354 related articles for article (PubMed ID: 35189703)
1. Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis.
Wang JK; Li Y; Zhao XL; Liu YB; Tan J; Xing YY; Adi D; Wang YT; Fu ZY; Ma YT; Liu SM; Liu Y; Wang Y; Shi XJ; Lu XY; Song BL; Luo J
Circulation; 2022 Mar; 145(9):675-687. PubMed ID: 35189703
[TBL] [Abstract][Full Text] [Related]
2. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
4. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
5. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
10. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 and atherosclerosis: Looking beyond LDL regulation.
Ragusa R; Basta G; Neglia D; De Caterina R; Del Turco S; Caselli C
Eur J Clin Invest; 2021 Apr; 51(4):e13459. PubMed ID: 33236356
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (
Burke AC; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Barrett PHR; Newton RS; Pickering JG; Huff MW
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1178-1190. PubMed ID: 29449335
[TBL] [Abstract][Full Text] [Related]
14. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
[TBL] [Abstract][Full Text] [Related]
15. Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr
Jeurissen MLJ; Walenbergh SMA; Houben T; Gijbels MJJ; Li J; Hendrikx T; Oligschlaeger Y; van Gorp PJ; Binder CJ; Donners MMPC; Shiri-Sverdlov R
Atherosclerosis; 2016 Dec; 255():59-65. PubMed ID: 27816810
[TBL] [Abstract][Full Text] [Related]
16. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
[TBL] [Abstract][Full Text] [Related]
17. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
[TBL] [Abstract][Full Text] [Related]
18. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.
Jiang H; Zhang J; Du Y; Jia X; Yang F; Si S; Wang L; Hong B
Atherosclerosis; 2015 Dec; 243(2):523-32. PubMed ID: 26523989
[TBL] [Abstract][Full Text] [Related]
19. The COMMD Family Regulates Plasma LDL Levels and Attenuates Atherosclerosis Through Stabilizing the CCC Complex in Endosomal LDLR Trafficking.
Fedoseienko A; Wijers M; Wolters JC; Dekker D; Smit M; Huijkman N; Kloosterhuis N; Klug H; Schepers A; Willems van Dijk K; Levels JHM; Billadeau DD; Hofker MH; van Deursen J; Westerterp M; Burstein E; Kuivenhoven JA; van de Sluis B
Circ Res; 2018 Jun; 122(12):1648-1660. PubMed ID: 29545368
[TBL] [Abstract][Full Text] [Related]
20. Local effects of human PCSK9 on the atherosclerotic lesion.
Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
